Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emily Hayes

San Francisco, CA
Emily Hayes is a writer/editor with over 20 years’ experience in medical journalism, including magazines for specialist clinicians, government health publications, business newswires and pharma trade press.  Her educational background lies in journalism and political science. Emily has dual citizenship and has experience working in the UK and US. Since 2008, she has been a senior writer on staff with “The Pink Sheet,” working out of her home base in biopharma hub San Francisco. She enjoys covering drug development, with special areas of focus in cancer, particularly immunotherapy, and cardiology/metabolics. She covers major scientific meetings regularly, including the American Society of Clinical Oncology, and appreciates interactions with key opinion leaders while interpreting drug trial results. In her free time, she is a professional jazz/blues/country vocalist.
Advertisement
Set Alert for Articles By Emily Hayes

Latest From Emily Hayes

Pharmas Join To Build Inflammation Biomarkers In Alzheimer's, Depression

Drug firms exploring link between inflammation and central nervous system disorders are now sharing resources through public/private Biomarkers Consortium project.
Clinical Trials Research & Development

FDA Flags Lower Efficacy For Merck's Keytruda, Roche's Tecentriq In Frontline Bladder Cancer Trials

In patients with previously untreated metastatic bladder cancer with low PD-L1 expression, PD-1 drugs alone don't work as well as chemo.

ImmunoOncology Approvals

Immuno-Oncology: What To Watch At ASCO 2018

Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.

ImmunoOncology Clinical Trials

Other ASCO 2018 Highlights – It’s Not All IO

The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET. 

Clinical Trials Cancer

Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin

Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.

Companies Research & Development

NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.

See All
Advertisement
UsernamePublicRestriction

Register